Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes

Rituximab (R) with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is the current standard of care as first-line treatment for diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype. Patients who fail R-CHOP have a poor outcome with relapse or refractory disease res...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Lei, Li, Lindong, Zhou, Yiqun, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155827/
https://www.ncbi.nlm.nih.gov/pubmed/32300390
http://dx.doi.org/10.14740/jh320w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155827/
https://www.ncbi.nlm.nih.gov/pubmed/32300390
http://dx.doi.org/10.14740/jh320w

Ejemplares similares